Interview: Paolo Casati – General Manager, Santen Italy
Paolo Casati, general manager for Santen’s new affiliate in Italy, discusses the company’s first full year in the country, its aims for contributing to the global group’s 2020 Vision by…
In the last decade, Santen has strengthened its presence in Europe and has become a major player in the field of ophthalmology.
Santen is one of the few international companies specialized mainly in ophthalmology. Currently, Santen operates with leading university research centers and key opinion leaders in Europe to better understand diseases and illnesses. Basically, the work will be used to facilitate the diagnosis and management of these conditions.
Santen is committed to protect and improve eyesight, especially eye disorders that require new approaches to treatment.
The company has established its presence in Italy in 2014, in order to reflect its renewed determination to be patient-centric and expand in Europe.
Contact
Piazza Sigmund Freud, 1
20154 Milano
ITALIA
Tel.: +39 02 6200191
Fax: +39 02 62001999
Web: santen.eu/it
Paolo Casati, general manager for Santen’s new affiliate in Italy, discusses the company’s first full year in the country, its aims for contributing to the global group’s 2020 Vision by…
Biotechnologies have a significant role to play bringing Italy towards a more knowledge-based economy. What is the economic contribution of the sector today? According to the last Blossom Associati-Assobiotec report…
After long experience in the pharmaceutical industry, working in both multinational and local laboratories, you took the reins of the already well-established Italian subsidiary of Ferring a few months ago.…
Dr Fazi, you co-founded Eurogroup Consulting (EGC) in Italy in 2007 and are now leading a well established reality, renowned for the new model of governance it has designed. Could…
Following the successful result of the “Piano Sanitario Nazionale” 2005 – 2008, could you introduce to ours readers the key priorities and main health policies to be implemented by 2009…
Following 20 years of a comprehensive experience in diverse fields of the pharmaceutical industry, you entered Baxter in 2000. At the time, the Italian affiliate was already a well established…
Despite Italy being one of the most important pharmaceutical markets not only in Europe but also in the World, the industry remained quite stable for the last two years and…
Grunenthal-Formenti relies on Formenti’s 60 years experience in Italy and is the result of the merger of both the German and Italian entities in 96. How would you describe the…
Having led a 26 years long career in Pfizer, you have been involved in a number of different countries including leading markets such as the US and Japan, but also…
You have worked in other countries such as the UK and the US with very large and significant pharmaceutical industries. What would you say is particular about the Italian pharmaceutical…
Since 1982, CNR has been the Italian public body which most contributed to the creation of inventions and innovations. What have been the main strategies behind such a success in…
Over more than 25 years, PAREXEL has expanded its global footprint through a combination of organic growth, alliances, and acquisitions. What was the rationale behind entering Italy in 1995 and…
Roche Italy is one of the companies which went through the most significant re-organization process in the country in the past three years- with important changes in both its marketing…
See our Cookie Privacy Policy Here
